136 related articles for article (PubMed ID: 36137305)
21. Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma: A case report.
Ma S; Sen SS; Jug R; Zhang X; Zhang WL; Shen S; Yu CQ; Xu HT; Yang LH; Wang E
Medicine (Baltimore); 2018 Sep; 97(38):e12482. PubMed ID: 30235749
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
[TBL] [Abstract][Full Text] [Related]
23. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
[TBL] [Abstract][Full Text] [Related]
24. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas.
Schroers R; Baraniskin A; Heute C; Kuhnhenn J; Alekseyev A; Schmiegel W; Schlegel U; Pels HJ
Eur J Haematol; 2010 Sep; 85(3):236-42. PubMed ID: 20528903
[TBL] [Abstract][Full Text] [Related]
25. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
26. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
Oka S; Ono K; Nohgawa M
Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
[TBL] [Abstract][Full Text] [Related]
27. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
28. Primary central nervous system lymphoma.
Bhagavathi S; Wilson JD
Arch Pathol Lab Med; 2008 Nov; 132(11):1830-4. PubMed ID: 18976024
[TBL] [Abstract][Full Text] [Related]
29. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
[TBL] [Abstract][Full Text] [Related]
30. [Case of primary central nervous system lymphoma after open head injury].
Honma M; Ota M; Sato N; Ogawa K; Sugino T; Yamamoto T
Rinsho Shinkeigaku; 2012; 52(5):329-35. PubMed ID: 22688112
[TBL] [Abstract][Full Text] [Related]
31. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology.
Schroers R; Baraniskin A; Heute C; Vorgerd M; Brunn A; Kuhnhenn J; Kowoll A; Alekseyev A; Schmiegel W; Schlegel U; Deckert M; Pels H
Eur J Haematol; 2010 Dec; 85(6):520-8. PubMed ID: 20727005
[TBL] [Abstract][Full Text] [Related]
33. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
34. A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors.
Sromek M; Rymkiewicz G; Paziewska A; Szafron LM; Kulecka M; Zajdel M; Kulinczak M; Dabrowska M; Balabas A; Bystydzienski Z; Chechlinska M; Siwicki JK
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572608
[TBL] [Abstract][Full Text] [Related]
35. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS).
Camilleri-Broët S; Martin A; Moreau A; Angonin R; Hénin D; Gontier MF; Rousselet MC; Caulet-Maugendre S; Cuillière P; Lefrancq T; Mokhtari K; Morcos M; Broët P; Kujas M; Hauw JJ; Desablens B; Raphaël M
Am J Clin Pathol; 1998 Nov; 110(5):607-12. PubMed ID: 9802345
[TBL] [Abstract][Full Text] [Related]
36. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
Zheng J; Xu J; Ma S; Sun X; Geng M; Wang L
Int J Clin Exp Pathol; 2013; 6(10):2048-55. PubMed ID: 24133582
[TBL] [Abstract][Full Text] [Related]
38. Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide.
Madabhavi IV; Revannasiddaiah S; Sarkar MS; Modi MG
Oral Oncol; 2019 Jun; 93():122-124. PubMed ID: 31010638
[TBL] [Abstract][Full Text] [Related]
39. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
40. [CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].
Magomedova AU; Misyurina AE; Mangasarova JK; Gorenkova LG; Margolin OV; Fastova EA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):35-40. PubMed ID: 32598734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
